Genzyme CEO Henri A. Termeer On Big Pharma’s Transformation To Becoming Leaner Machines: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
Genzyme CEO Henri A. Termeer, has seen his company grow from a small entrepreneurial venture into one of the world's largest biotech companies. Having held several prestigious positions like deputy chairman of the Federal Reserve Bank of Boston's board of directors and chairman of the board of Medical Simulation Corp, Termeer is recognized globally for his contributions in the field of biotechnology. With a growth record of 20 percent annually for the past five years, Termeer is now looking beyond American shores to keep with the growth momentum. In an interview with PharmAsia News' India bureau during a World Economic Forum meeting in New Delhi, Termeer speaks on the challenges of the global pharmaceutical industry and the role of emerging markets like India and China.
You may also be interested in...
In India, Sanofi-Aventis Scores Good Results But Integration With Genzyme Will Be Key To Draw Benefits From Deal
MUMBAI - It was a busy day at Sanofi-Aventis' Indian headquarters as the European firm's nine-month long pursuit to buy specialty biotech Genzyme culminated on the day its Indian arm announced its full year and fourth quarter earnings data to investors
In India, Sanofi-Aventis Scores Good Results But Integration With Genzyme Will Be Key To Draw Benefits From Deal
MUMBAI - It was a busy day at Sanofi-Aventis' Indian headquarters as the European firm's nine-month long pursuit to buy specialty biotech Genzyme culminated on the day its Indian arm announced its full year and fourth quarter earnings data to investors
Genzyme CEO Henri A. Termeer On Big Pharma’s Transformation To Becoming Leaner Machines: An Interview With PharmAsia News (Part 1 of 2)
Genzyme CEO Henri A. Termeer has seen his company grow from a small entrepreneurial venture into one of the world's largest biotech companies. Having held several prestigious positions like deputy chairman of the Federal Reserve Bank of Boston's board of directors and chairman of the board of Medical Simulation Corp, Termeer is recognized globally for his contributions in the field of biotechnology. With a growth record of 20 percent annually for the past five years, Termeer is now looking beyond American shores to keep with the growth momentum. In an interview with PharmAsia News' India bureau during a World Economic Forum meeting in New Delhi, Termeer speaks on the challenges of the global pharmaceutical industry and the role of emerging markets like India and China.